Oncolytics Biotech Stock (NASDAQ:ONCY)


ForecastOwnershipChartTranscripts

Previous Close

$1.18

52W Range

$0.33 - $1.53

50D Avg

$0.61

200D Avg

$0.79

Market Cap

$106.59M

Avg Vol (3M)

$1.02M

Beta

1.19

Div Yield

-

ONCY Company Profile


Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

28

IPO Date

Oct 05, 2001

Website

ONCY Performance


Latest Earnings Call Transcripts


Q1 25May 14, 25 | 4:30 PM
Q4 24Mar 07, 25 | 8:30 AM
Q3 24Nov 13, 24 | 8:30 AM

Peer Comparison


TickerCompany
IOVAIovance Biotherapeutics, Inc.
XERSXeris Biopharma Holdings, Inc.
SCPHscPharmaceuticals Inc.
CYCCCyclacel Pharmaceuticals, Inc.
DMACDiaMedica Therapeutics Inc.
VTVTvTv Therapeutics Inc.
MCRBSeres Therapeutics, Inc.
ATYRaTyr Pharma, Inc.
TRAWTraws Pharma, Inc.